<DOC>
	<DOCNO>NCT01345864</DOCNO>
	<brief_summary>This study design look potential investigational drug ( PF-04995274 , development Pfizer , Inc. potential treatment Alzheimer 's disease ) reverse change memory learning/problem solve skill cause co-administration market drug call scopolamine . Scopolamine know cause temporary change memory learning/problem solve skill similar see people alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Assessment Of The Effects Of Single Doses Of An Investigational Drug , Given Alone Or With Donepezil , On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults</brief_title>
	<detailed_description>Changes sponsor 's organizational strategy lead decision terminate study therefore conduct second cohort ( Cohort B/arms 2 3 ) . This decision base significant safety concern . Date termination ( ie , date site notify stop study activity ) 12 Oct 2011 .</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Healthy male female volunteer ; female must nonchildbearing potential . Weight normal limit height . Willing comply study schedule able complete 2 practice session ( prestudy ) computerize memory learning/problem solve test . Positive urine drug screen ; concurrent use prescription overthecounter ( OTC ) drug dietary supplement within 7 day 5 halflives prior first dose study medication . Use medication significant serotonergic , cholinergic anticholinergic side effect [ SSRIs , pyridostigmine , tricyclic antidepressant , meclizine , oxybutynin ] ) within 4 week first dose study drug . Glaucoma Abnormal electrocardiogram ( ECG ) Treatment investigational drug within 30 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>attention cognition memory problem solve scopolamine challenge</keyword>
</DOC>